Exelixis (EXEL) Osake Kurssi
Exelixis Kurssi
Viimeisten 19 vuoden aikana Exelixisn liikevaihto kasvoi 18,1 % vuodessa ja ylsi 2,32 Mrd. USD:een. Osakekohtainen tulos on kasvanut 11,8 % vuodessa viimeisten 14 vuoden aikana. Exelixisn nettomarginaali 33,7 % on noussut verrattuna 16,1 %:iin muutama vuosi sitten. Exelixisn 12 kuukauden konsensustavoitehinta on 52,00 USD, noin ali kurssia 12,4 %. 27 analyytikosta 12 suosittaa ostoa — kokonaiskonsensus on Pidä.
Exelixis osakekurssi
Exelixis liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Exelixis -osakkeesta
The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.
Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.
Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.
Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.
Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.
Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer.
Analyytikot asettavat tällä hetkellä Exelixis-osakkeelle keskimääräisen tavoitehinnan 51,78 USD (mediaani: 52,00 USD), mikä merkitsee −12,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 27 analyytikkoarvioon.
27 analyytikkoa arvioi tällä hetkellä Exelixis-osaketta: 12 suosittaa ostoa, 14 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Exelixis-yhtiöltä 2,55 Mrd. USD liikevaihtoa ja 3,51 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Exelixis-osake noteerataan hintaan 53,01 EUR (59,33 USD).
Exelixis-osake (EXEL) on listattuna 8 pörssissä, muun muassa: NASDAQ (EXEL), London (0IJO.L), SIX (Zürich) (EX9.SW), XETRA (EX9.DE), Frankfurt (EX9.F), München (EX9.MU), Düsseldorf (EX9.DU).
Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.
odotettu liikevaihto Exelixis on 2,55 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Exelixis on 988,25 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Exelixis:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,92. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Exelixis-osakkeen arvostusta.
Exelixis:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,55. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Exelixis-osakkeen arvostuskennuslukuna.
Exelixis:n Eulpool-laatuscore on 6/10.
Exelixis:n ISIN on US30161Q1040. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Exelixis:n WKN on 936718. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Exelixis:n ticker on EXEL. Tämä pörssinoteeraus käytetään Exelixis-osakkeiden kauppaan pörssissä.
Exelixis osake
Exelixis vertaisryhmä
Exelixis Ticker
Exelixis FIGI
Kaikki tunnusluvut ja syvällinen analyysi Exelixis:sta
Meidän osakeanalyysimme Exelixis-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Exelixis:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: